Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
83%(5 trials)

Phase Distribution

Ph phase_2
1
17%
Ph phase_3
3
50%
Ph phase_4
2
33%

Phase Distribution

0

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
3(50.0%)
Phase 4Post-market surveillance
2(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (16.7%)
Phase 33 (50.0%)
Phase 42 (33.3%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_4

Hepatitis B Vaccination in Infants

NCT01896596
completedphase_4

Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine

NCT00454987
completedphase_3

Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines

NCT00463437
completedphase_3

Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants

NCT00586612
completedphase_2

Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants

NCT00871338
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT01896596Phase 4

Hepatitis B Vaccination in Infants

Completed
NCT00454987Phase 4

Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine

Completed
NCT00463437Phase 3

Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines

Completed
NCT00586612Phase 3

Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants

Completed
NCT00871338Phase 2

Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants

Completed
NCT00384059Phase 3

Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6